Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.

Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo, Viola Ghizzoni, Francesco Raspagliesi, Marilena Di Napoli, Enrica Mazzoni, Claudia Marchetti, Alice Bergamini, Michele Orditura, Giorgio Valabrega, Giovanni Scambia, Giuseppa MalteseElisabetta De Matteis, Cinzia Cardalesi, Vera Loizzi, Serena Boccia, Emanuele Naglieri, Giuseppa Scandurra, Sandro Pignata

Research output: Contribution to journalArticlepeer-review

Abstract

Olaparib is approved as maintenance therapy in patients with BRCA mutated platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based therapy. Few data are available regarding the use out of the registration trials and on response to further treatments after progression. In this non interventional, retrospective study, patients treated with olaparib in 13 centers, according to the label, have been collected and analyzed. Primary objectives of the study are to describe effectiveness and safety of olaparib in a real world setting with a focus on post progression treatments and response. 234 patients were analyzed. All patients were BRCA mutated and most of them had germline mutations. Around 50% of the patients received olaparib after 3 or more lines of platinum based chemotherapy achieving a radiologic complete (CR) or partial response. 12.4% patients with stable disease were also included. Median PFS was 14.7 months (95% CI:12.6-18), with statistically longer PFS in patients with normal serum Ca125 at baseline, a CR after last platinum based therapy and that received olaparib after second platinum based therapy. Median OS was not reached. Most frequent G3-G4 toxicity was anaemia (6%) with dose discontinuation and dose reduction in 11 (4.7%) and 49 (20.9%) of cases, respectively. Among 66 patients receiving further treatment after olaparib progression and evaluable for response, ORR was 22.2, 11.1% and 9.5% in patients with Platinum Free interval (PFI) of more than 12 months, between 6 and 12 months and less than 6 months, respectively. Olaparib is effective and safe in real world setting. Data on post-progression treatments seem to suggest cross resistance with chemotherapy and need to be confirmed in larger studies because of the potential importance in clinical practice decisions.
Original languageUndefined/Unknown
Pages (from-to)38-44
Number of pages7
JournalGynecologic Oncology
Volume156
DOIs
Publication statusPublished - Jan 1 2020

Keywords

  • Antineoplastic Agents
  • administration & dosage
  • BRCA1 Protein
  • genetics
  • BRCA2 Protein
  • Female
  • Genes
  • BRCA1
  • BRCA2
  • Germ-Line Mutation
  • Humans
  • Maintenance Chemotherapy
  • Middle Aged
  • Neoplasm Recurrence
  • Local
  • drug therapy
  • Organoplatinum Compounds
  • Ovarian Neoplasms
  • Phthalazines
  • Piperazines
  • Progression-Free Survival
  • Retrospective Studies
  • Maintenance
  • Olaparib
  • Ovarian cancer
  • Post progression
  • Real world

Cite this